SLRX
Salarius Pharmaceuticals, Inc.0.7170
-0.0630-8.08%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
4.20MP/E (TTM)
-Basic EPS (TTM)
-24.24Dividend Yield
0%Recent Filings
8-K
New exec trio hired
Salarius signed employment agreements on November 18, 2025, with Frederick E. Pierce as CEO, Barbara Hibner as CSO, and Peter Marschel as CBO—effective upon Decoy Therapeutics merger closing. Each gets $225,000 base salary plus 35% target bonus. Severance equals one year's pay plus nine months COBRA. New team readies post-merger push.
10-Q
Q3 FY2025 results
Salarius trimmed Q3 operating expenses 11% y/y to $895K while R&D plunged 55% y/y to $62K, driving net loss to $873K from $972K; nine-month operating loss eased 16% y/y to $3.6M. Cash climbed to $4.8M on $6.5M equity raises, burning $3.7M in operations. Shares outstanding ballooned post-reverse splits, fueling EPS improvement to $(1.81) from $(11.38). Merger with Decoy closed November 12, 2025, adding peptide conjugate pipeline. Cash funds operations through Q1 2027. Nasdaq compliance regained October 10. Reverse splits preserved listing. Yet dilution risk looms large.
8-K
Merger bonus approved
Salarius Pharmaceuticals approved a $225,000 cash transaction bonus for Acting CEO and CFO Mark J. Rosenblum on October 21, 2025, payable upon closing the merger with Decoy Therapeutics, provided he remains employed through that date. This incentive aligns leadership with the ongoing merger process, amended multiple times since January. Bonus ties directly to deal success. Yet the closing timeline remains undisclosed.
8-K
Regains Nasdaq equity compliance
Salarius Pharmaceuticals regained compliance with Nasdaq's minimum stockholders' equity rule on October 10, 2025, following its earlier bid price recovery, putting it fully in line with listing standards amid its planned merger with Decoy Therapeutics. The deal, announced January 13, 2025, will rebrand the entity as Decoy and integrate Salarius' SP-3164 into peptide-based PROTACs, while advancing Decoy's pipeline toward an IND filing for a pan-coronavirus antiviral within 12 months. Yet a one-year monitor looms. Non-compliance could trigger delisting.
8-K
Salarius boosts equity via stock sales
Salarius Pharmaceuticals raised $6.2 million through recent stock sales—$2.4 million from 434,882 shares via an at-the-market offering and $3.8 million from 367,887 shares to C/M Capital Master Fund—pushing stockholders' equity above Nasdaq's $2.5 million threshold as of October 6, 2025. This move aims to secure continued listing on the Nasdaq Capital Market by the October 20 deadline. Equity now exceeds the minimum. Yet Nasdaq's final confirmation remains pending, with preliminary figures subject to quarter-end adjustments.
IPO
Employees
Sector
Industry
ALXO
ALX Oncology Holdings Inc.
1.43+0.03
AURA
Aura Biosciences, Inc.
6.18-0.15
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
MNPR
Monopar Therapeutics Inc.
71.47-3.65
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
SLXN
Silexion Therapeutics Corp
2.61+0.05
TNGX
Tango Therapeutics, Inc.
8.96-0.16
XLO
Xilio Therapeutics, Inc.
0.65+0.00